La Roche-Posay and L'Oréal redefine the possibilities of smart skincare technology with EFFACLAR SPOTSCAN

After MY UV Patch, La Roche-Posay is taking a step further in skincare technology with  EFFACLAR SPOTSCAN, the first acne analyzer powered by artificial intelligence

MONTREAL, March 28, 2019 /CNW/ - Today, La Roche-Posay, expert of sensitive skin and #1 brand recommended by dermatologists in Canada¹, proves once again its commitment to providing a better life for sensitive skin with the launch of EFFACLAR SPOTSCAN, a breakthrough innovation that uses artificial intelligence, based on extensive scientific data, to make personalized acne analyses. Approved by dermatologists and powered by artificial intelligence, EFFACLAR SPOTSCAN springs from La Roche-Posay's commitment to using technology to provide consumers with the right acne analysis, the right information and the right personalized recommendations for effective results and better skin health.

After MY UV Patch, La Roche-Posay is taking a step further in skincare technology with EFFACLAR SPOTSCAN, the first acne analyzer powered by artificial intelligence (CNW Group/La Roche-Posay)

Today, acne remains the skin indication that affects the most Canadians and is the top concern for which Canadians consult a physician. While medical expertise can help, there is only one dermatologist for every 70,000 Canadians. With EFFACLAR SPOTSCAN, La Roche-Posay's ambition is to provide acne management expertise by offering personalized recommendations to better manage acne.

To build the most accurate and innovative algorithm, La Roche-Posay brought together dermatologists from around the world to analyze more than 6,000 images of men and women representing different ethnicities, skin types and levels of acne severity. EFFACLAR SPOTSCAN is the result of a close partnership with dermatologists and its accuracy has been validated through a clinical study.

"Today consumers want more than just great skincare from a brand, they want an experience. Service has become the new-age product," says Emma Kindler, General Manager of La Roche-Posay Canada. "We know that information is power when it comes to skin health and to improve their skin, consumers need to understand it. For acne sufferers, this means learning how to manage their acne, and it all starts with an accurate analysis. With EFFACLAR SPOTSCAN we pursue our brand mission even further to create a better life for sensitive skin."

EFFACLAR SPOTSCAN is very easy to use and takes only a few moments to complete. The instant analysis provides an acne score from 0 to 4+. Based on the analysis, the service outlines a personalized Effaclar routine and specific skincare tips. The before/after skin improvement simulator shows the expected results and allows users to follow along with their skin's progress through the Skin Diary.

The Skin Diary is the most visionary aspect of EFFACLAR SPOTSCAN to help consumers evaluate their acne results. When patients look at their skin every day, they don't always notice their progress, which may lead to discouragement. With EFFACLAR SPOTSCAN's Skin Diary, patients can take photos before and during the acne treatment, to make the results easier to see. This new ability motivates consumers to follow their acne treatment to ultimately improve their lives with acne.

Canadians can easily find EFFACLAR SPOTSCAN on https://ca.spotscan.com.

ABOUT LA ROCHE-POSAY
Deep-rooted in dermatological heritage, La Roche-Posay has for over 40 years placed its expertise in sensitive skin at the center of its products. As such, since 2015 the brand has held the coveted position as being the #1 brand recommended by dermatologists in Canada. La Roche-Posay is a division of L'Oréal Canada, a wholly-owned subsidiary of L'Oréal Group, the largest cosmetics company in the world.

_______________________

¹ Source, Canadian study IQVIA 2018.

SOURCE La Roche-Posay

Axelle Techer, The Colony Project on behalf of La Roche-Posay, T: 438.390.2803, E: [email protected]